NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Narendra Modi
    Amit Shah
    Box Office Collection
    Bharatiya Janata Party (BJP)
    OTT releases
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout


    India Business World Politics Sports Technology Entertainment Auto Lifestyle Inspirational Career Bengaluru Delhi Mumbai Visual Stories Find Cricket Statistics Phones Reviews Fitness Bands Reviews Speakers Reviews

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
     
    Home / News / India News / COVAXIN likely to get approval for children above 2yrs: Report
    COVAXIN likely to get approval for children above 2yrs: Report
    1/5
    India 2 min read

    COVAXIN likely to get approval for children above 2yrs: Report

    By Pratyush Deep Kotoky
    Apr 22, 2022
    10:37 am
    COVAXIN likely to get approval for children above 2yrs: Report
    A government panel is also reportedly evaluating Bharat Biotech's data on children above 2 years.

    Bharat Biotech's COVID-19 vaccine, COVAXIN, is likely to get the Drugs Controller General of India's (DCGI) nod for use among children aged two to 12 years. The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) is considering sending recommendations on COVAXIN to DCGI, reported News18. A government panel is also reportedly evaluating Bharat Biotech's data on children above two years.

    2/5

    Why does this story matter?

    Vaccination of children has now become the government's priority as India is witnessing a fresh surge in COVID-19 cases, especially among kids. Notably, India has so far not included children below 12 years in its national vaccination drive. For those aged 12-18 years, two vaccines—Biological E's Corbevax (for the 12-14 years age group) and COVAXIN (for the 15-18 age group)—have so far been authorized.

    3/5

    Bharat Biotech submitted data from its clinical trials last year

    To recall, Bharat Biotech had last year submitted its data from its clinical trials in the 2-18 years age group for COVAXIN to the CDSCO. In October 2021, the SEC had also recommended emergency use authorization (EUA) of COVAXIN for children aged 2 to 18 years, but with certain conditions. However, DCGI granted later granted COVAXIN the EUA only for children above 12 years.

    4/5

    SEC recommends Corbevax for children aged 5 to 12

    Meanwhile, the SEC had earlier also reportedly recommended the use of Biological E's Corbevax in children aged 5-12 years. Also, a government panel had previously convened a meeting to discuss data and the use of Corbevax in children in this age bracket, reported News18.

    5/5

    Current COVID-19 situation in India

    India on Friday reported 2,451 new COVID-19 cases and 54 more deaths in the last 24 hours. This marks an increase of nearly 100 cases from the previous day. The active caseload in the country has also been witnessing an increasing trend and stood at 14,241 on Friday. While India's total cases rose to 4,30,52,425, the recovery rate stood at 98.75%

    Facebook
    Whatsapp
    Twitter
    Linkedin
    Related News
    Drugs Controller General of India
    COVID-19
    Bharat Biotech
    COVAXIN
    COVID-19 Vaccination

    Drugs Controller General of India

    Biological E's Corbevax vaccine approved for children aged 12-18 years COVID-19
    COVAXIN, Covishield will now be available in hospitals and clinics COVID-19
    New anti-COVID drug may cost up to Rs. 3,000: Report World Bank
    J&J vaccine's 1cr doses ready for export after CDL nod Johnson & Johnson

    COVID-19

    COVID-19 in India: States where wearing masks are mandatory again Delhi
    Don't think current COVID-19 surge is fourth wave: ICMR ex-head Delhi
    IPL 2022: One more Delhi Capitals player tests COVID-19 positive Indian Premier League (IPL)
    COVID-19: Delhi makes masks mandatory again with Rs. 500 fine Coronavirus Cases In India

    Bharat Biotech

    COVAXIN supply to be increased as teens get COVID-19 vaccines COVID-19
    Are Indian vaccines effective against Omicron? Here's what manufacturers say Zydus Cadila
    COVAXIN gets WHO approval for emergency use listing World Health Organization
    Australia accepts COVAXIN as 'recognized' vaccine for incoming travelers India

    COVAXIN

    COVAXIN found 50% effective against COVID-19 in first real-world study COVID-19
    UK to add COVAXIN to approved vaccines from November 22 World Health Organization
    COVID-19: India reports 11K new cases, 526 more deaths Coronavirus
    COVAXIN under review; may get WHO recommendation in 24 hours World Health Organization

    COVID-19 Vaccination

    COVID-19: India reports 2,067 new cases, 40 deaths COVID-19
    COVID-19: India reports 1,247 new cases, one death COVID-19
    UP: Wearing masks now mandatory in Lucknow, 6 NCR districts Delhi
    COVID-19: India logs 2,183 new cases, 214 more deaths COVID-19
    Next News Article

    Love India News?

    Subscribe to stay updated.

    India Thumbnail
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2023